论文部分内容阅读
目的:探讨奥沙利铂联合参芪扶正注射液对原发性肝癌患者AFP,GP73及临床疗效的影响。方法:收集我院收治的原发性肝癌患者80例,随机分为对照组和实验组,每组各40例,对照组患者给予奥沙利铂联合卡培他滨化疗,实验组患者在此基础上给予参芪扶正注射液静脉滴注。观察并比较两组患者治疗前后血清AFP及GP73水平、生活质量以及临床疗效。结果:与治疗前相比,两组患者的AFP、GP73水平均下降,差异具有统计学意义(P<0.05);与对照组相比,实验组患者的AFP、GP73水平较高,生活质量提高率较高,差异具有统计学意义(P<0.05),临床治疗总有效率以及总稳定率较高,差异具有统计学意义(P<0.05)。结论:奥沙利铂联合参芪扶正注射液能够降低原发性肝癌患者AFP,GP73水平,提高患者生活质量,临床疗效较好。
Objective: To investigate the effect of oxaliplatin combined with Shenqi Fuzheng injection on AFP and GP73 in patients with primary liver cancer and its clinical effect. Methods: Eighty patients with primary liver cancer admitted to our hospital were randomly divided into control group and experimental group, 40 cases in each group. Patients in control group were given oxaliplatin combined with capecitabine chemotherapy. Patients in experimental group On the basis of given Shenqi Fuzheng injection intravenous drip. The levels of serum AFP and GP73, quality of life and clinical efficacy before and after treatment were observed and compared between the two groups. Results: The levels of AFP and GP73 in both groups were significantly lower than those before treatment (P <0.05). Compared with the control group, the AFP and GP73 levels in the experimental group were significantly higher and the quality of life improved The difference was statistically significant (P <0.05), the total effective rate of clinical treatment and the total stable rate were higher, the difference was statistically significant (P <0.05). Conclusion: Oxaliplatin combined with Shenqi Fuzheng injection can reduce the levels of AFP and GP73 in patients with primary liver cancer and improve the quality of life of patients with good clinical efficacy.